Overview

The Use of Blinatumomab in Patients With NGS-MRD Relapsed B-ALL After Autologous/Allogeneic Transplantation

Status:
NOT_YET_RECRUITING
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
To explore the efficacy and safety ofblinatumomab± TKI in B-ALL patients aged ≥ 14 years with NGS-MRD relapse (sensitivity: 10-6) after auto/allo HSCT, and to observe the disease-free survival (DFS), recurrence rate and toxicity after transplantation.
Phase:
NA
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China
Treatments:
blinatumomab